Colorectal cancer - an undertreated disease

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 623-629

  Kemeny, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Colorectal cancer; Fluorouracil; Leucovorin; Thymidylate synthase inhibitors; Topoisomerase I inhibitors

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; THYMIDYLATE SYNTHASE INHIBITOR;

ADJUVANT CHEMOTHERAPY; COLORECTAL CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN;

EID: 0029970874     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00001     Document Type: Review

References (84)

1. Schmoll H-J. Colorectal cancer: current problems and future perspectives. Ann Oncol 1994; 5(Suppl 3): S115-24.
2. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. J Am Mad Ass 1990; 264: 1444-50.
3. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumour development. N Engl J Med 1988; 319: 525-32.
4. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Eng J Med 1994; 331: 1669-74.
5. Goldbohm RA, van den Brandt PA, van't Veer P, Dorant E, Sturmans F, Hermus RJ. Cholecystectomy and colorectal cancer; evidence from a cohort study on diet and cancer, Int J Cancer 1993; 53: 735-9.
6. Giovannucci E, Rimm EB, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US men. J Natl Cancer Inst 1994; 86: 183-91.
7. Burnstein MJ. Dietary factors related to colorectal neoplasms. Surg Clin North Am 1993; 73: 13-29.
8. Milsom JW. The pathogenesis of colorectal cancer. Cancer 1993; 73: 1-12.
9. Holzman D. Genetic clues about colon cancer reshape treatment approaches. J Natl Cancer Inst 1995; 87: 708-10.
10. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995; 332: 861-7.
11. Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10: 79-84.
12. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Eng J Med 1985; 312: 1465-72.
13. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-15.
14. O'Connell M, Wieand H, Krook J, et al. Lack of value of methyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy. Interim analysis of intergroup protocol 86-47-51. Proc Am Soc Clin Oncol 1991; 10: 134 (abstr).
15. O'Connell M, Martenson J, Rich T, et al. Protracted venous infusion (PVI) 5-fluorouracil (5-FU) as a component of effective combined modality post-operative surgical adjuvant therapy for high-risk rectal cancer. Proc Am Soc Clin Oncol 1993; 12: 193 (abstr).
16. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg 1989; 210: 127-38.
17. Nogueras JJ, Jagelman DG. Principles of surgical resection. Influence of surgical technique on treatment outcome. Surg Clin North Am 1993; 73: 103-16.
18. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomised trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559-65.
19. Cricca A, Martoni A, Guaraldi M, Fruet F, Pannuti F. Randomized clinical trial of 5-FU + folinic acid vs 5-FU in advanced gastrointestinal cancers. Proc Eur Soc Med Oncol 1988; 13: 427.
20. Erlichman C, Fine S, Wong A, Elhakim T. A randomised trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
21. Nohile MT, Vidili MG, Sobrero A, et al. 5-fluorouracil alone or combined with high-dose leucovorin in advanced colorectal cancer patients. Proc Am Soc Clin Oncol 1988; 7: 371.
22. Di Costanzo F, Bartolucci R, Sofra M, et al. 5-fluorouracil alone vs high dose folinic acid and 5-FU in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Proc Am Soc Clin Oncol 1989; 8: 106 (abstr).
23. Labianca R, Pancera G. A randomized study of intravenous fluorouracil ± folinic acid (FA) in advanced metastatic colorectal cancer (AMC). Proc Am Soc Clin Oncol 1989; 8: 118 (abstr).
24. Petrelli N, Douglass HO, Herrera L, et al The modulation of fluorouracil with leucovorin in metastatic colorectal cancer: a prospective randomized phase III trial. J Clin Oncol 1989: 7: 1419-26.
25. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-18.
26. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin. A randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427-36.
27. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomised comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491-501.
28. Steinke B, Giunther E, Hirschman W-D, et al. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer - preliminary results of a randomized trial. Semin Oncol 1991; 18: 141-7.
29. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 1993; 5: 52-5.
30. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995; 13: 1303-11
31. Advanced Colorectal cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced CRC: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
32. Moertel CG. Chemotherapy and colorectal cancer. N Engl J Med 1994; 330: 1136-42.
33. Kemeny NE, Ahmed T, Michaelson R, Harper HD, Yip LC. Activity of sequential low dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. J Clin Oncol 1984; 2: 311-5.
34. Burnet R, Smith FP, Hoerni B, Lagarde C, Schein P. Sequential methotrexate, 5-fluorouracil in advanced measurable colorectal cancer Lack of appreciable therapeutic synergism. Proc Am Ass Cancer Res 1981; 22: 370 (abstr).
35. Blumenreich MS, Woodcock TM, Allegra M, Richman SP, Kubota TT, Allegra JC. Sequential therapy with methotrexate (MTX) and 5-fluorouracil (5-FU) for adenocarcinoma of the colon. Proc Am Soc Clin Oncol 1982; 1: 102 (abstr).
36. Cantrell JE, Brunet R, Lagarde C, Schein PS, Smith FP. Phase II study of sequential methotrexate 5-FU therapy in advanced measurable colorectal cancer. Cancer Treat Rep 1982; 66: 1563-5.
37. Coates AS, Hedley D, Fox RM, Raghavan D, Tattersall MH. Randomized trial of sequential methotrexate (M) following 5-fluorouracil (F) versus F followed by M. Proc Am Ass Cancer Res 1983; 24: 140.
38. Anjani JA, Kanojia MD, Bedikian AY, et al. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol 1985; 8: 69-71.
39. Benz C, DeGregorio M, Saks S, et al. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity and response. Cancer Res 1985; 45: 3354-8.
40. Panasci L, Ford J, Margolese R. A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer, Cancer Chemother Pharmacol 1985; 15: 164.
41. Glimelius B, Ginman C, Graffman S, Pahlman L, Stahle E. Sequential methotrexate 5-FU leucovorin (MFL) in advanced colorectal cancer. Eur J Cancer Clin Oncol 1986; 22: 295-300.
42. Hansen RM, Quebbeman EJ, Ritch PS, Frick J, Anderson T Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. Am J Clin Oncol 1987; 10: 216-8.
43. Mackintosh J, Coates A, Swanson C, Raghavan D, Tattersall MHN. Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil. Am J Clin Oncol 1987; 10: 210 12.
44. Marsh JC, Bertino JR, Katz KH, et al. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991; 9: 371-80.
45. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769-75.
46. Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027-31.
47. Kemeny N, Younes A, Seiter K, et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer 1990; 66: 2470-5.
48. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A: 2077-9.
49. Washtien WL, Santi DV. Assay of intracellular and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. Cancer Res 1979; 39: 397 404.
50. Schackney SE. Cell kinetics and cancer chemotherapy. In: Calbresi P, Schein PS, Roseneberg SA, eds. Medical oncology. New York: Macmillan 1985; 41-60.
51. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-8.
52. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
53. Hansen R, Ryan L, Anderson T, Quebbeman E, Haller D. A phase III trial of bolus 5FU versus protracted infusion 5FU ± cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 1991; 10: 154 (abstr).
54. Kemeny N, Seiter K. Treatment options for patients with metastatic colorectal cancer. In. Niederhuber JE, ed. Current therapy in oncology. St Louis, MO: Mosby-Year Book 1993: 447-57.
55. Kemeny N, Seiter K, Conti J, et al. Hepatic arterial FUDR and leucovorin in previously untreated patients with unresectable liver metastatses from colorectal carcinoma. Cancer 1994; 73: 1134-42.
56. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine (FUDR) with dexamethasone versus FUDR alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-34.
57. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-8.
58. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-60.
59. Wolmark N, Rockette H, Wickerham DL, et al. The benefit of leucovorin modulated fluoruracil as post-operative adjuvant therapy for primary colon cancer: results from the National Surgical Adjuvant Breast and Bowel Project protocol C-O3. J Clin Oncol 1993; 11: 1879-87.
60. Franchini G, Petrioli R, Wong A, et al. Folinic acid 5-fluorouracil as adjuvant therapy in colon cancer. Gastroenterology 1994; 106: 899-906.
61. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
62. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-6.
63. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Eng J Med 1990; 322: 352-8.
64. Reynolds T. Dutch trial casts doubt on colorectal adjuvant therapy (news). J Natl Cancer Inst 1995; 87: 476-9.
65. Takimoto CH. Enigma of fluorouracil and levamisole (editorial: comment). J Natl Cancer Inst 1995; 87: 471-3.
66. Scheithauer W, Rosen H, Kornek G-V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5.
67. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden P-O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
68. Glimelius B, Hoffman K, Graf W, et al. Cost effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74.
69. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-11.
70. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD. Recent advances in the treatment of advanced colorectal cancer. Cancer 1993; 71: 9-18.
71. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. Br Med J 1990; 300: 1458-60.
72. Machover D, Goldschmidt E, Chollet P, et al. A treatment of advanced colorectal and gastric adenocarcinoma with 5-FU and high dose folinic acid. J Clin Oncol 1986; 4: 685-96.
73. De Gramont A, Krulik M, Cady J, et al. High dose folinic acid and 5-FU bolus as continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499-503.
74. McLeish JA, Giles GG, Thursfield V. Investigation, follow-up and recurrence after resection of colorectal cancer. Aust NZ J Surg 1992; 62: 931-40.
75. Crosby T, Hockley B. The pattern of colorectal cancer referrals to oncologists from surgeons for adjuvant chemotherapy based on pathological state. Br J Cancer 1995; 72 (suppl XXV): 9 (abstr).
76. Dalgliesh AG. Chemotherapy for solid tumours. Br Med J 1995; 310: 1328-9.
77. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
78. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
79. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
80. Bugat R, Rougier P, Brunet P, et al. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer (CRC): results of a multicentric open phase II study. In Proc 5th Int Congr of Anti-cancer Chemotherapy, Paris, 1995, S775 (abstr).
81. Conti JA, Kemeny N, Saltz L, Tong W, Chou TC, Pulliam M. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC). In Proc 30th Annu Meeting of the American Society of Clinical Oncology, Dallas, 1994 (abstr).
82. Kerr D, Cunningham D, Zalcberg J, et al. 'Tomudex' (ZD1694) has superior response and toxicity profiles compared to 5-fluorouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): first results of a large international phase III study. Br J Cancer 1995; 72 (suppl XXV): 10 (abstr).
83. Cunningham D, Zalcberg JR, Rath U, et al. Tomudex (ZD1694), a new and effective therapy for advanced colorectal cancer has a significantly lower incidence of severe mucositis and leucopenia than standard therapy: results of an open, randomised multicentre trial of Tomudex versus 5-fluorouracil (5-FU) and leucovorin (LV). Eur J Cancer 1995, submitted.
84. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83.